143
Participants
Start Date
April 30, 2013
Primary Completion Date
September 30, 2014
Study Completion Date
October 24, 2018
DNA-HIV-PT123 vaccine
DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
NYVAC-HIV-PT1 vaccine
NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid
NYVAC-HIV-PT4 vaccine
NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid
Placebo for DNA-HIV-PT123 vaccine
Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
Placebo for NYVAC-HIV-PT1 vaccine
Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
Placebo for NYVAC-HIV-PT4 vaccine
Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
Lausanne Vaccine and Immunotherapy Center CRS, Lausanne
Penn Prevention Crs, Philadelphia
The Hope Clinic of the Emory Vaccine Center CRS, Decatur
Alabama CRS, Birmingham
UIC Project WISH CRS, Chicago
Bridge HIV CRS, San Francisco
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston
Seattle Vaccine and Prevention CRS, Seattle
National Institute of Allergy and Infectious Diseases (NIAID)
NIH